
The Optimist
Brock the Bull
Sees the upside in every cap table and orders another round to celebrate it.

A short-form show · Now pouring
A bull and a bear argue over live startup raises, so you hear both sides before you invest.
Tonight's pour
Ep. 8
A stem cell shot at brain injury in newborns.
A bull, a bear, and an owl debate Axiom Biosciences, a stem cell biotech targeting brain injury in newborns. Early clinical data and federal grants on one side; a small Phase 1 trial, a long regulatory road, and hard-to-sell shares on the other. Read the offering and the risks, then decide for yourself.
Free episode. Axiom Biosciences is not a client of Pre-IPO Hype and did not pay for this episode.
Usual seats

The Optimist
Sees the upside in every cap table and orders another round to celebrate it.

The Skeptic
Reads the risk factors first. Asks about burn rate before he asks your name.

The Bartender
Pours, listens, and closes every episode with the verdict.
"Bull sees the upside. Bear sees the risk. Read the offering and decide for yourself."
For founders
Running a Reg CF, Reg A+ or Reg D raise? Put it in front of the bull and the bear. We feature live offerings and link viewers straight to your offering page and SEC filings.